We are live on ! Find out more
O

OppenheimerFunds Portfolio holdings

AUM $80.4B
1-Year Est. Return 15.1%
This Fund
S&P 500
This Quarter Est. Return
+6.63%
1 Year Est. Return
+15.1%
3 Year Est. Return
+72.05%
5 Year Est. Return
+91.1%
10 Year Est. Return
AUM
$82.8B
AUM Growth
+$1.44B
Cap. Flow
-$2.02B
Cap. Flow %
-2.43%
Top 10 Hldgs %
16.17%
Holding
1,933
New
90
Increased
882
Reduced
857
Closed
96

Top Buys

Rank Stock Value
1
EBAY icon
eBay
EBAY
+$366M
2
KMX icon
CarMax
KMX
+$273M
3
ORLY icon
O'Reilly Automotive
ORLY
+$240M
4
MSI icon
Motorola Solutions
MSI
+$212M
5
BABA icon
Alibaba
BABA
+$201M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$401M
2
FTI icon
TechnipFMC
FTI
+$399M
3
AZO icon
AutoZone
AZO
+$327M
4
CSCO icon
Cisco
CSCO
+$232M
5
NTES icon
NetEase
NTES
+$181M

Sector Composition

Rank Sector Weight
1 Financials 15.41%
2 Consumer Discretionary 14.11%
3 Energy 13.48%
4 Healthcare 12.91%
5 Technology 11.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GIFI
1826
DELISTED
Gulf Island Fabrication
GIFI
$137K ﹤0.01%
10,148
-1,480
-13% -$18.7K
DGII icon
1827
Digi International
DGII
$2.52B
$120K ﹤0.01%
12,560
-1,918
-13% -$19.6K
HK
1828
DELISTED
Halcon Resources Corporation
HK
$115K ﹤0.01%
15,246
-487
-3% -$3.34K
CRR
1829
DELISTED
Carbo Ceramics Inc.
CRR
$106K ﹤0.01%
10,441
-771
-7% -$6.82K
CDR
1830
DELISTED
Cedar Realty Trust, Inc
CDR
$104K ﹤0.01%
2,596
-444
-15% -$17.2K
GEF.B icon
1831
Greif Class B
GEF.B
$3.65B
$71K ﹤0.01%
+1,017
New +$65K
PACB icon
1832
Pacific Biosciences
PACB
$422M
$33K ﹤0.01%
+12,662
New +$44.3K
LBTYK icon
1833
Liberty Global Class C
LBTYK
$3.27B
$15K ﹤0.01%
+443
New +$13.6K
BF.A icon
1834
Brown-Forman Class A
BF.A
$12.3B
$12K ﹤0.01%
+228
New +$10.9K
HEI.A icon
1835
HEICO Corp Class A
HEI.A
$35.4B
$8K ﹤0.01%
+161
New +$7.87K
HK.WS
1836
DELISTED
Halcon Resources Corporation
HK.WS
$2K ﹤0.01%
+3,494
New +$2.1K
AMPH icon
1837
Amphastar Pharmaceuticals
AMPH
$825M
-11,663
Closed -$208K
APEI icon
1838
American Public Education
APEI
$875M
-11,273
Closed -$237K
AXDX
1839
DELISTED
Accelerate Diagnostics
AXDX
-26,521
Closed -$5.95M
BAH icon
1840
Booz Allen Hamilton
BAH
$8.7B
-502,684
Closed -$18.8M
BCH icon
1841
Banco de Chile
BCH
$20.6B
-44,881
Closed -$1.33M
BKLN icon
1842
Invesco Senior Loan ETF
BKLN
$7.1B
-3,351,165
Closed -$77.6M
CAE icon
1843
CAE Inc. Common Shares
CAE
$8.1B
-5,441,613
Closed -$95.2M
CNQ icon
1844
Canadian Natural Resources
CNQ
$96.9B
-597,563
Closed -$9.8M
DSGX icon
1845
Descartes Systems
DSGX
$5.84B
-877,846
Closed -$23.9M
EEFT icon
1846
Euronet Worldwide
EEFT
$3.02B
-189,330
Closed -$17.9M
EHTH icon
1847
eHealth
EHTH
$42.5M
-21,620
Closed -$517K
EMBJ
1848
Embraer S.A. ADS
EMBJ
$11.6B
-3,850,399
Closed -$87.1M
EVH icon
1849
Evolent Health
EVH
$475M
-813,523
Closed -$14.5M
FIBK icon
1850
First Interstate BancSystem
FIBK
$3.7B
-14,392
Closed -$550K

Similar funds

OppenheimerFunds's Q4 2017 Portfolio in Review

As of Q4 2017, OppenheimerFunds held 1,933 positions worth $82.8B, up 1.8% from $81.4B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

OppenheimerFunds's Q4 2017 filing shows 90 new, 882 increased, 857 reduced and 96 closed positions. Its largest new stake was Nebius Group N.V.: 5,110,710 shares worth $167M. The largest sale was Nektar Therapeutics, an estimated $401M.

By sector, the portfolio is most concentrated in Financials at 15% of assets, up from 15% a quarter earlier, followed by Consumer Discretionary and Energy.

  • OppenheimerFunds's largest Q4 2017 buy was Nebius Group N.V.: 5,110,710 shares worth $167M.
  • OppenheimerFunds added most to eBay in Q4 2017, an estimated $366M increase.
  • OppenheimerFunds's biggest Q4 2017 reduction was Nektar Therapeutics, cutting an estimated $401M.
  • OppenheimerFunds fully exited NetEase in Q4 2017, selling an estimated $181M.
  • OppenheimerFunds's ten largest holdings make up 16% of its $82.8B portfolio in Q4 2017.
  • OppenheimerFunds opened 90 new positions and closed 96 in Q4 2017.
  • OppenheimerFunds's portfolio value rose 1.8% quarter-over-quarter to $82.8B.

Based on OppenheimerFunds's 13F filing for Q4 2017, filed 12 Feb 2018.